Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Acute promyelocytic leukemia is a variant of acute myeloid leukemia characterised by t(15;17) and PML/RAR alfa fusion gene. The invention of the molecular pathogenesis has led to entitle all-trans retinoic acid (ATRA) as the primary focused remedy for acute leukemia. It’s often related to anthracycline-based chemotherapy with excessive response charges, however potential long-term sequelae together with therapy-related malignancies have been noticed.
Arsenic trioxide (ATO) was added to obviate these issues and investigational trials aimed to a brand new technique with the incorporation of arsenic trioxide (ATO) into preliminary remedy as an alternative of chemotherapy in chosen sufferers. ATRA plus ATO with out chemotherapy was the primary try to deal with low and intermediate-risk sufferers with APL. Our examine goals to explain a monocentric cohort of sufferers with newly recognized APL successfully handled with ATO plus ATRA underlying its efficacy along with the excessive grade of tolerability of this affiliation.
From January 2009 to December 2019 23 APL sufferers have been recognized and handled with ATO plus ATRA routine: 14 males and 9 females sufferers with a median age of 45 years (vary 18-72), for almost all intermediate threat (15 sufferers, 65%). The remedy was properly tolerated and all sufferers achieved molecular remission after a median time of three months (vary 1-6 months). All sufferers proceeded to consolidation section as outpatients, they maintained full molecular response at a median time of 44 months (vary 15-127) apart from 1 affected person.
All however one affected person are alive and in response at a median follow-up of 48 months (vary 9-141) with out late results. ATO plus ATRA routine exhibits benefits compared to chemotherapy; actually it allowed to deal with sufferers during which chemotherapy may even not be relevant and it didn’t present secondary hematological ailments. The affiliation of ATO to ATRA as chemo-free routine enabled to deal with APL even with out chemotherapy.

Investigation of the ameliorative results of baicalin in opposition to arsenic trioxide-induced cardiac toxicity in mice

Baicalin (BA), a form of flavonoids compound, comes from Scutellaria baicalensis Georgi (a form of perennial herb) and has useful results on the cardiovascular system by means of anti-oxidant, anti-inflammation, and anti-apoptosis actions. Nevertheless, the therapeutic results and latent mechanisms of BA on arsenic trioxide (ATO)-induced cardiac toxicity has not been reported. The current analysis was carried out to discover the results and mechanisms of BA on ATO-induced coronary heart toxicity.
Male Kunming mice have been handled with ATO (7.5 mg/kg) to induce cardiac toxicity. After the mice obtained ATO, BA (50 and 100 mg/kg) was administered for estimating its cardioprotective results. Statistical information demonstrated that BA remedy alleviated electrocardiogram abnormalities and pathological harm attributable to ATO.
BA may additionally result in restoration of CK and LDH actions to regular vary and trigger a lower in MDA ranges and ROS technology, augmentation of SOD, CAT, and GSH actions. We additionally discovered that BA prompted a discount within the expression of proinflammatory cytokines, akin to TNF-α and IL-6. Furthermore, BA attenuated ATO-induced apoptosis by selling the expression of Bcl-2 and suppressing the expression of Bax and caspase-3. TUNEL take a look at consequence demonstrated BA prompted obstacle of ATO-induced apoptosis.
Moreover, BA remedy suppressed the excessive expression of TLR4, NF-κB and P-NF-κB attributable to ATO. In conclusion, these outcomes point out that BA might alleviate ATO-induced cardiac toxicity by restraining oxidative stress, apoptosis, and irritation, and its mechanism can be related to the inhibition of the TLR4/NF-κB signaling pathway.

Comparative Analysis of Mineral Trioxide Mixture Obturation Utilizing 4 Totally different Methods-A Laboratory Research

This examine aimed to check the density of mineral trioxide combination (MTA) as a root canal filling materials within the apical 5 mm of synthetic root canals. Forty clear acrylic blocks with 30-degree curved canals have been instrumented and allotted into 4 compaction method teams (n = 10): Lawaty (hand recordsdata); gutta-percha (GP) factors; auger (nickel-titanium rotary recordsdata in reverse mode); and plugger method. Crammed canals have been weighed after setting the MTA to calculate distinction in mass.
Two postoperative radiographs in contrast radiopacity by measuring luminance variations at 0.5 mm, 1 mm, 2 mm, Three mm, four mm, and 5 mm from the basis apex. Obturation time was measured utilizing a digital chronometer. The importance stage was set to p < 0.05. The plugger group had a decrease mass. Relative luminance was considerably greater for the Lawaty group than the plugger group in any respect examined apical ranges.
The relative luminance of the auger and GP teams have been considerably greater than the plugger group at depths between 0.5 mm and a couple of mm. Relative luminance was highest for the Lawaty method in any respect depths between 0.5 mm and four mm. The Lawaty method group was related to elevated obturation time in contrast with pluggers. Compacting MTA in curved canals with the Lawaty method has the best mass and radiopacity however requires extra time.
 Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience

Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency

In this study, arsenic trioxide (ATO) was encapsulated in liposomes via copper acetate (Cu(OAc)2) gradients and high entrapment efficiency of over 80% was obtained. The average particle size and the zeta-potential of the liposomes were detected to be 115.1 ± 29.1 nm and -21.97 ± 0.6 mV, respectively.
The TEM images showed rod-like precipitates in the inner aqueous phase, which was supposed be due to the formation of insoluble ATO-Cu complex. The in vitro drug release of ATO-Cu liposomes exhibited a sustained release over 72 h, and the release rates decreased with the increase of the pH of release media. Pharmacokinetic and tissue distribution studies of ATO liposomes showed significantly reduced plasma clearance rate, increased AUC0-12 h and T1/2, and improved tumor distribution of As compared to iv administration of ATO solution.
The anti-tumor effect of ATO loaded liposomes to S180 tumor-bearing mice was significantly improved with a tumor inhibition rate of 61.2%, meanwhile the toxicity of encapsulated ATO was greatly decreased.

Rat Androgen Receptor (AR) ELISA Kit

DLR-AR-Ra-48T 48T
EUR 528
  • Should the Rat Androgen Receptor (AR) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids.

Rat Androgen Receptor (AR) ELISA Kit

DLR-AR-Ra-96T 96T
EUR 690
  • Should the Rat Androgen Receptor (AR) ELISA Kit is proven to show malperformance, you will receive a refund or a free replacement.
Description: A sandwich quantitative ELISA assay kit for detection of Rat Androgen Receptor (AR) in samples from tissue homogenates, cell lysates or other biological fluids.

Human Androgen Receptor (AR) ELISA Kit

RDR-AR-Hu-48Tests 48 Tests
EUR 522

Human Androgen Receptor (AR) ELISA Kit

RDR-AR-Hu-96Tests 96 Tests
EUR 724

Mouse Androgen Receptor (AR) ELISA Kit

RDR-AR-Mu-48Tests 48 Tests
EUR 534

Mouse Androgen Receptor (AR) ELISA Kit

RDR-AR-Mu-96Tests 96 Tests
EUR 742

Rat Androgen Receptor (AR) ELISA Kit

RDR-AR-Ra-48Tests 48 Tests
EUR 558

Rat Androgen Receptor (AR) ELISA Kit

RDR-AR-Ra-96Tests 96 Tests
EUR 776

Human Androgen Receptor (AR) ELISA Kit

RD-AR-Hu-48Tests 48 Tests
EUR 500

Human Androgen Receptor (AR) ELISA Kit

RD-AR-Hu-96Tests 96 Tests
EUR 692

Mouse Androgen Receptor (AR) ELISA Kit

RD-AR-Mu-48Tests 48 Tests
EUR 511

Mouse Androgen Receptor (AR) ELISA Kit

RD-AR-Mu-96Tests 96 Tests
EUR 709

Rat Androgen Receptor (AR) ELISA Kit

RD-AR-Ra-48Tests 48 Tests
EUR 534

Rat Androgen Receptor (AR) ELISA Kit

RD-AR-Ra-96Tests 96 Tests
EUR 742

Molybdenum(VI) oxide, 99.9%

GX8007-100G 100 g
EUR 130

Molybdenum(VI) oxide, 99.9%

GX8007-1KG 1 kg
EUR 389

Molybdenum(VI) oxide, 99.9%

GX8007-250G 250 g
EUR 183

Ar/ Rat Ar ELISA Kit

ELI-04146r 96 Tests
EUR 886

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

20-abx113870
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 Protein

20-abx263321
  • EUR 1609.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 10 ug
  • 2 µg
  • Shipped within 5-10 working days.

Molybdenum Cofactor Sulfurase (MOCOS) Antibody

abx235263-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

AR Antibody

32572-100ul 100ul
EUR 252

AR antibody

10R-2031 100 ul
EUR 403
Description: Mouse monoclonal AR antibody

AR Antibody

1-CSB-PA006094
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/10000

AR Antibody

CSB-PA001975KA01HU-
EUR 335
  • Form: liquid
  • Buffer: Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. Affinity purification
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100

AR Antibody

CSB-PA001975KA01HU-100ul 100ul
EUR 389
  • Form: liquid
  • Buffer: Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3. Affinity purification
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, ICC;WB:1:500-1:1000, IHC:1:50-1:100, ICC:1:50-1:100

AR Antibody

1-CSB-PA056943
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
  • Form: Liquid
  • Buffer: -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol Antigen affinity purification
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100

AR Antibody

1-CSB-PA05979A0Rb
  • EUR 317.00
  • EUR 335.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Preservative: 0.03% Proclin 300
    Constituents: 50% Glycerol, 0.01M PBS, PH 7.4 >95%, Protein G purified
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

AR 231453

B3269-10 10 mg
EUR 245
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors.

AR 231453

B3269-5 5 mg
EUR 179
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors.

AR 231453

B3269-5.1 10 mM (in 1mL DMSO)
EUR 195
Description: AR 231453 is an agonist of GPR119 with EC50 value of 0.68nM [1].AR 231453 is the first subnanomolar agonist of GPR119. It is highly selective against GPR119 over a 76 receptor and enzyme profiling panel (CEREP) including the known incretin receptors.

AR Antibody

DF6783 200ul
EUR 304
Description: AR Antibody detects endogenous levels of total AR.

AR antibody

70R-35838 100 ug
EUR 327
Description: Rabbit polyclonal AR antibody

AR A014418

20-abx076761
  • EUR 718.00
  • EUR 314.00
  • 25 mg
  • 5 mg
  • Shipped within 5-12 working days.

AR Antibody

BF0418 200ul
EUR 376
Description: AR antibody detects endogenous levels of total AR.

AR Antibody

1-CSB-PA011255
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/40000

AR Antibody

1-CSB-PA011256
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AR. Recognizes AR from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/40000

AR Antibody

1-CSB-PA011257
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse. This antibody is Unconjugated. Tested in the following application: IHC, IF, ELISA;IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000

AR Antibody

1-CSB-PA011258
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
  • Form: Liquid
  • Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Description: A polyclonal antibody against AR. Recognizes AR from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

AR siRNA

20-abx900461
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AR siRNA

20-abx908237
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AR siRNA

20-abx908238
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol
  • Shipped within 5-10 working days.

AR Antibody

ABD6783 100 ug
EUR 438

AR-A014418

A3184-10 10 mg
EUR 128
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor.

AR-A014418

A3184-5.1 10 mM (in 1mL DMSO)
EUR 123
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor.

AR-A014418

A3184-50 50 mg
EUR 268
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor.

AR-A014418

A3184-S Evaluation Sample
EUR 81
Description: IC50: 104 ± 27 nMGlycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer?s disease (AD). AR-A014418 is a selective GSK-3 inhibitor.

AR-C155858

A3185-10 10 mg
EUR 991
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members.

AR-C155858

A3185-5 5 mg
EUR 611
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members.

AR-C155858

A3185-50 50 mg
EUR 2800
Description: AR-C155858 is a potent and selective inhibitor of monocarboxylate transporters MCT1 and MCT2 with Ki values of 2.3nM and less than 10 nM, respectively [1].MCT is a monocarboxylate transporter family with 14 members.

AR-C155858

HY-13248 10mM/1mL
EUR 483

AR 231453

HY-15564 10mM/1mL
EUR 160

AR-A014418

HY-10512 50mg
EUR 342

AR-9281

HY-111151 5mg
EUR 211

AR-08

HY-U00371 20mg
EUR 13439

pCDNA3.1-AR

PVT18102 2 ug
EUR 300

Clematichinenoside AR

TBW00371 10mg
EUR 847

ar-Tumerone

TBW01373 5mg Ask for price

AR-C155858

B2743-1 1 mg
EUR 348

KAF/AR/ Rat KAF/ AR ELISA Kit

ELA-E0006r 96 Tests
EUR 886

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

abx025653-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

abx025653-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

20-abx005887
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

20-abx113871
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

abx036894-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

abx037731-100ug 100 ug
EUR 391
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

20-abx131326
  • EUR 439.00
  • EUR 133.00
  • EUR 1233.00
  • EUR 592.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

20-abx131327
  • EUR 425.00
  • EUR 133.00
  • EUR 1205.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug
  • Shipped within 5-7 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

20-abx135733
  • EUR 411.00
  • EUR 592.00
  • EUR 182.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

abx028710-400ul 400 ul
EUR 523
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

abx028710-80l 80 µl
EUR 286
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

20-abx321401
  • EUR 439.00
  • EUR 328.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

20-abx321402
  • EUR 439.00
  • EUR 328.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

abx235264-100ug 100 ug
EUR 481
  • Shipped within 5-12 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

20-abx321947
  • EUR 439.00
  • EUR 328.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 1 (MOCS1) Antibody

20-abx322547
  • EUR 439.00
  • EUR 328.00
  • 100 ul
  • 50 ul
  • Shipped within 5-10 working days.

Molybdenum Cofactor Synthesis 2 (MOCS2) Antibody

20-abx304514
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug
  • Shipped within 5-10 working days.

Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1)

4-RPC623Hu01
  • EUR 503.20
  • EUR 238.00
  • EUR 1612.00
  • EUR 604.00
  • EUR 1108.00
  • EUR 400.00
  • EUR 3880.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q9NZB8
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 21.5kDa
  • Isoelectric Point: Inquire
Description: Recombinant Human Molybdenum Cofactor Synthesis 1 expressed in: E.coli

Recombinant Molybdenum Cofactor Synthesis 1 (MOCS1)

4-RPC623Mu01
  • EUR 458.40
  • EUR 226.00
  • EUR 1444.00
  • EUR 548.00
  • EUR 996.00
  • EUR 370.00
  • EUR 3460.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
  • Uniprot ID: Q5RKZ7
  • Buffer composition: PBS, pH 7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
  • Form: Freeze-dried powder
  • Predicted Molecular Mass (KD): 22.4kDa
  • Isoelectric Point: Inquire
Description: Recombinant Mouse Molybdenum Cofactor Synthesis 1 expressed in: E.coli

Beta3-AR Antibody

3939-200
EUR 354

Beta3-AR Antibody

3939-30T
EUR 146

AR Polyclonal Antibody

41904-100ul 100ul
EUR 252

AR Polyclonal Antibody

41904-50ul 50ul
EUR 187

AR-beta3 Antibody

44295-100ul 100ul
EUR 252

AR-beta3 Antibody

44295-50ul 50ul
EUR 187

AR Polyclonal Antibody

40609-100ul 100ul
EUR 252

AR Polyclonal Antibody

40609-50ul 50ul
EUR 187

AR Polyclonal Antibody

40610-100ul 100ul
EUR 252

AR Polyclonal Antibody

40610-50ul 50ul
EUR 187

AR-M 1896

B5328-1 1 mg
EUR 486
Description: Binding IC50: 1.76 nM for rGalR2; 879 nM for hGalR1Galanin is a 29-aa neuropeptide with a complex role in pain processing. Galanin receptor subtypes are present in dorsal root ganglia and spinal cord with a differential distribution.

AR-C 102222

B5504-10 10 mg
EUR 421

AR-C 102222

B5504-50 50 mg
EUR 1617

AR Blocking Peptide

DF6783-BP 1mg
EUR 195

AR-42J cells

C0018004 One Frozen vial
EUR 455

AR Conjugated Antibody

C32572 100ul
EUR 397

Netarsudil (AR-13324)

B7807-2 2 mg
EUR 305
Description: Ki: 0.43141.3 nMNetarsudil (AR-13324) is a ROCK inhibitor.The Rho kinases are serine/threonine protein kinases existing as 2 isoforms, ROCK1 and ROCK2, which are widely expressed in various tissues, such as the trabecular meshwork.
In conclusion, ATO can be effectively encapsulated into liposomes by remote loading method via Cu(OAc)2 gradients; the co-administration of ATO and Cu(II) via liposomal formulation may find wide applications in the treatment of various tumors.

Leave a Reply

Your email address will not be published. Required fields are marked *